ARCH Venture Partners led a $135m series A round in City Therapeutics.

ARCH Venture Partners, an American venture capital firm, led a $135m series A round in City Therapeutics, a biopharmaceutical company harnessing next-generation engineering of small interfering RNAs, with participation from Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures and AN Ventures. “As an early investor in Alnylam, ARCH supported the creation of RNAi medicines as a new frontier of medicine. The time to re-enter the RNAi revolution is now, and our investment in City Therapeutics is based on our conviction that RNAi therapeutics will expand as a major category of breakthrough medicines,” Robert Nelsen, ARCH Venture Partners Co-Founder and Managing Director.